This corroborated over-expression of IFN-signalling has an immediate foreseeable opportunity for potential therapeutic exploitation via anifrolimab, FDA-approved for systemic lupus erythematosus. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.